

Catalog# BP- 50577

## Belatacept Biosimilar (Nulojix, CTLA-4 Fc Fusion Protein)

Belatacept (trade name Nulojix, Bristol-Myers-Squibb), a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Belatacept differs from abatacept (trade name Orencia) by only 2 amino acids.

The CTLA-4 protein is important for T-cell costimulation and selectively blocks the process of T-cell activation.

Product Details	
CAS No.	706808-37-9
Species Reactivity	Human
Source	Nulojix biosimilar CHO stable cell line
Isotype	Human immunoglobulin gamma 1 (hIgG1)
Class	Monoclonal
Type	Antibody
Clone	Belatacept Biosimilar
Conjugate	Unconjugated
Immunogen	Human CD80 (B7-1) with more avidity than to CD86 (B7-2)
Purity	>95%
Molecular Weight	90 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 $\mu$ M filtered PBS solution, pH 7.2-7.8
Storage conditions	4°C for short time, -20°C or -80°C for long time.